10-Q: Abeona Therapeutics Reports Q3 Income Surge on ZEVASKYN PRV Sale

Abeona Therapeutics reported a significant net income for the nine months ended September 30, 2025, driven by the sale of its ZEVASKYN Priority Review Voucher, despite initial manufacturing challenges for its newly approved gene therapy.

Summary

• Abeona Therapeutics Inc. reported a net income of $91.6 million for the nine months ended September 30, 2025, a substantial improvement from a net loss of $54.4 million in the prior year period.
• The significant income was primarily due to a $152.4 million net gain from the sale of a Priority Review Voucher (PRV) following the FDA approval of ZEVASKYN.
• ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), received FDA approval on April 28, 2025.
• A full batch of ZEVASKYN manufactured in August 2025 could not be released due to a false positive sterility assay result, leading to a temporary pause in patient biopsy collection.
• The company optimized the rapid sterility release assay and resumed biopsy collection in November 2025.
• Research and development expenses decreased by $5.3 million to $20.1 million for the nine months ended September 30, 2025, primarily due to costs being capitalized into inventory and reclassified post-FDA approval.
• Selling, general and administrative expenses increased significantly by $24.0 million to $46.2 million, driven by commercialization efforts, legal costs, and new hires.
• Cash and cash equivalents increased to $82.9 million as of September 30, 2025, from $23.4 million at December 31, 2024.
• Total cash resources, including short-term investments and restricted cash, stood at $207.5 million as of September 30, 2025.
• The company expects its current cash resources to fund operations for at least the next 12 months from the report date.
• A Loan Agreement Amendment on July 18, 2025, reduced the interest rate on senior secured term loans from 13.5% to a fixed rate of 11.75% per annum.
• The 'One Big Beautiful Bill Act,' enacted on July 4, 2025, favorably impacted income tax, restoring immediate expensing of domestic R&D and 100% bonus depreciation, resulting in a $15.2 million current income tax benefit for Q3 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the landmark FDA approval of ZEVASKYN, the substantial cash infusion from the PRV sale, and improved financial metrics. However, it is tempered by the initial manufacturing delay for ZEVASKYN, increased commercialization expenses, and the ongoing need for future capital, as well as the uncertainty surrounding NOL utilization.

Positives

• Achieved FDA approval for ZEVASKYN on April 28, 2025, as the first and only autologous cell-based gene therapy for RDEB.
• Generated significant net income of $91.6 million for the nine months ended September 30, 2025, primarily from the $152.4 million net gain on the sale of a Priority Review Voucher (PRV).
• Strong liquidity position with total cash resources of $207.5 million as of September 30, 2025, expected to fund operations for at least the next 12 months.
• Reduced interest rate on senior secured term loans from 13.5% to 11.75% per annum through a July 2025 amendment.
• ABO-503 for X-linked retinoschisis (XLRS) was selected for the FDA's Rare Disease Endpoint Advancement Pilot (RDEA) Program, indicating enhanced regulatory support.
• Activated a new ZEVASKYN Qualified Treatment Center (QTC) at Children's Hospital Colorado, expanding patient access.
• Secured a permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J3389) for ZEVASKYN, effective January 1, 2026, which is crucial for reimbursement.
• The 'One Big Beautiful Bill Act' provided a $15.2 million current income tax benefit in Q3 2025 by restoring immediate R&D expensing and 100% bonus depreciation.

Negatives

• Experienced a manufacturing issue in August 2025 where a full batch of ZEVASKYN could not be released due to a false positive sterility assay result, leading to a temporary pause in patient biopsy collection.
• Selling, general and administrative expenses increased significantly by $24.0 million (109%) for the nine months ended September 30, 2025, reflecting high commercialization costs for ZEVASKYN.
• Despite the net income, operating activities still resulted in a net cash outflow of $58.4 million for the nine months ended September 30, 2025, indicating ongoing operational cash burn.
• The company has incurred significant operating losses and negative cash flows from operations since inception, excluding the PRV sale, and anticipates these will continue until ZEVASKYN generates sufficient revenue.
• The New York office sublease terminated in September 2025, eliminating future sublease income.

Risks

• Changes in U.S. trade policy, including current or future tariffs or other trade restrictions, could increase R&D expenses, disrupt the supply chain, cause manufacturing delays for ZEVASKYN, and hinder the development of preclinical candidates.
• The company's ability to successfully commercialize ZEVASKYN and generate significant revenue is uncertain and depends on market acceptance, reimbursement, patient enrollment, competition, intellectual property protection, and manufacturing capabilities.
• The ability to use net operating loss (NOL) carryforwards to offset future taxable income may be materially limited due to multiple ownership changes under Section 382 of the Internal Revenue Code, with analysis expected to be completed by December 31, 2025.
• Disruptions at the FDA and other government agencies, potentially caused by funding shortages, hiring freezes, or large-scale layoffs (e.g., Department of Government Efficiency initiatives), could delay regulatory reviews, approvals, and commercialization efforts.
• The biopharmaceutical product development process is highly speculative and involves substantial risk, making future viability difficult to assess, especially with limited prior product revenue.
• Unexpected side effects, loss of intellectual property protection, data integrity issues, manufacturing or supply chain problems, regulatory proceedings, or adverse publicity could significantly impact ZEVASKYN's commercial success and revenue.
• The company may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that could adversely affect its business.

Future Outlook

The company anticipates continued operating losses and negative cash flows from operations until ZEVASKYN generates sufficient revenue to achieve profitability. Research and development activities are expected to continue for advancing other product candidates towards potential regulatory approval. Selling, general, and administrative costs are also expected to increase as ZEVASKYN's commercialization efforts expand and other product candidates progress. The company expects its current cash resources to be sufficient to fund operations for at least the next 12 months, but may need to raise additional capital to fully implement its business plans.

Management Comments

• "We expect that our capital resources will be sufficient to fund our on-going operations for the next 12 months from the issuance date of these unaudited condensed consolidated financial statements."
• "We may need to raise additional capital to fully implement its business plans through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans."
• "We expect our research and development activities to continue as we work towards advancing other product candidates towards potential regulatory approval."
• "We expect our selling, general, and administrative costs to continue to increase as we launch ZEVASKYN and advance other product candidates toward potential regulatory approval."
• "We are currently in the process of determining if a Section 382 change has occurred and to what extent the use of its NOL carryforwards may be limited. Preliminary results indicate that the Company has experienced multiple ownership changes and may have a material limitation on the use of its NOL carryforwards. The Company expects to complete its Section 382 analysis by December 31, 2025."

Industry Context

Abeona Therapeutics operates in the highly specialized and capital-intensive biopharmaceutical sector, focusing on cell and gene therapies for rare, life-threatening diseases. The FDA approval of ZEVASKYN positions the company as a commercial-stage entity, a significant milestone in the gene therapy space, particularly for a rare genetic skin disease like RDEB with no existing cure. The selection of ABO-503 for the FDA's RDEA Program highlights the industry's increasing focus on accelerating therapies for rare diseases through novel endpoint development. The establishment of a permanent J-code for ZEVASKYN is a critical step for market access and reimbursement, aligning with broader industry efforts to secure appropriate coding for advanced therapies. The manufacturing challenge faced by Abeona underscores the inherent complexities and stringent quality control required in gene therapy production, a common hurdle for companies in this innovative but challenging field. The 'One Big Beautiful Bill Act' reflects a dynamic regulatory and tax environment impacting R&D investment across the pharmaceutical industry.

Comparison to Industry Standards

• The FDA approval of ZEVASKYN for RDEB positions Abeona as a leader in autologous cell-based gene therapy for rare genetic skin diseases, a niche with high unmet medical need. This is comparable to other pioneering gene therapies for rare diseases, such as Novartis' Zolgensma for Spinal Muscular Atrophy or bluebird bio's Zynteglo for Beta-thalassemia, which also target severe conditions with limited treatment options.
• The sale of the Priority Review Voucher (PRV) for $155.0 million is consistent with market values for such vouchers, which typically range from $100 million to $150 million, reflecting the strategic value of expedited FDA review for future products. This is a common monetization strategy for companies developing therapies for rare pediatric diseases.
• The manufacturing issue with a false positive sterility assay result for ZEVASKYN is a known challenge in the cell and gene therapy industry, where complex biological manufacturing processes require extremely robust and rapid quality control methods. Companies like Sarepta Therapeutics and bluebird bio have also faced manufacturing and supply chain complexities for their gene therapies.
• The selection of ABO-503 for the FDA's Rare Disease Endpoint Advancement Pilot (RDEA) Program is a positive indicator, aligning with industry trends where regulatory bodies are actively collaborating with developers to facilitate clinical trial design and accelerate approvals for rare disease therapies. This program is designed to de-risk clinical development for novel endpoints, similar to initiatives seen with other rare disease drug developers seeking innovative trial designs.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Experienced significant increase in net income and stockholders' equity due to the PRV sale, but face potential future dilution from capital raises and uncertainty regarding NOL utilization. The manufacturing delay could impact commercial ramp-up and revenue generation.
• **Patients (RDEB)**: Benefit from the FDA approval of ZEVASKYN, the first and only autologous cell-based gene therapy for RDEB wounds. Expanded access through new QTCs and a permanent J-code will improve treatment availability and affordability. However, the temporary manufacturing pause caused delays for some patients.
• **Employees**: New hires and increased stock-based compensation indicate growth and investment in personnel, particularly in commercial and clinical development roles. The appointment of a new SVP for Clinical Development & Medical Affairs strengthens leadership.
• **Creditors (Avenue Venture Opportunities Fund)**: The Loan Agreement Amendment reduced the interest rate, potentially impacting their returns, but the company's improved liquidity from the PRV sale enhances its ability to meet debt obligations.
• **Regulatory Bodies (FDA, CMS)**: Continued engagement with FDA through the RDEA program and the establishment of a J-code with CMS demonstrate ongoing collaboration and compliance. The manufacturing issue highlights the FDA's stringent requirements for gene therapies.

Next Steps

• Continue commercialization efforts for ZEVASKYN, including enrolling new patients and expanding Qualified Treatment Centers (QTCs).
• Advance other AAV-based gene therapy product candidates (ABO-504, ABO-503, ABO-505) for ophthalmic diseases towards potential regulatory approval.
• Engage in enhanced communication and collaboration with the FDA as part of the Rare Disease Endpoint Advancement Pilot (RDEA) Program for ABO-503.
• Implement the permanent HCPCS J-code (J3389) for ZEVASKYN, effective January 1, 2026, to facilitate reimbursement.
• Complete the Section 382 analysis by December 31, 2025, to determine potential limitations on net operating loss (NOL) carryforwards.
• Monitor and adapt to potential impacts of U.S. trade policy changes and government agency disruptions on business operations and regulatory processes.

Key Dates

Recommendation

The FDA approval of ZEVASKYN and the substantial cash infusion from the PRV sale are significant positive catalysts, providing strong liquidity and validating the company's lead asset. However, the initial manufacturing delay for ZEVASKYN, while addressed, introduces uncertainty regarding the commercial ramp-up. The company also faces increased SG&A expenses for commercialization and potential limitations on NOL carryforwards. While the long-term potential of ZEVASKYN and the AAV pipeline is promising, the immediate commercial execution and the resolution of the NOL analysis warrant a 'hold' stance until clearer visibility on sustained revenue generation and operational efficiency is established. Investors should monitor ZEVASKYN's commercial uptake and further pipeline progress.

Keywords

ZEVASKYN, RDEB, Recessive Dystrophic Epidermolysis Bullosa, Gene Therapy, Cell Therapy, FDA Approval, Biopharmaceutical, Orphan Drug, Rare Pediatric Disease, Priority Review Voucher, AAV Capsids, Ophthalmic Diseases, Stargardt Disease, X-linked Retinoschisis, Autosomal Dominant Optic Atrophy, Clinical Development, Commercialization, SEC Filing, 10-Q, Financial Results, Liquidity, Capital Resources, Manufacturing, Regulatory Affairs, HCPCS J-code